The Russian branch of the Asian pharmaceutical company Takeda Pharmaceutical will invest 2.3 billion rubles in the creation of new production facilities on the basis of the Yaroslavl plant by 2027. The company will produce drugs against orphan diseases, according to the website of the Ministry of Industry and Trade.

The agreement was signed by Governor of the region Dmitry Mironov and CEO of Takeda Yaroslavl plant Chris Buttkus on the sidelines of the International Economic Forum in Saint-Petersburg.

As recalled the Governor of the Yaroslavl region, Takeda was among the first residents of the pharmaceutical cluster in the region. The corporation has invested about 9 billion rubles in the Yaroslavl production site since it started operating in Russia.

Takeda is engaged in the production of innovative medicines for the treatment of oncology, haematology, orphan and genetic diseases, gastroenterology, and neurology. The local authorities expect that the launch of the new production facility will have a positive effect on the economic development of the region.

"Due to the development of modern medicine and innovative technologies, some diseases have been transferred from the category of fatal to the category of chronic, controllable and preventable severe complications, as well as increased life expectancy of patients with rare diseases. As we are striving to increase the availability of innovative therapies for patients we are localizing the production of drugs in Russia, primarily at our plant in Yaroslavl," says Elena Kartasheva, President of Takeda Russia.

The company has already started producing drugs against multiple myeloma this year, with the Yaroslavl plant becoming Takeda's second site in the world where the drug is made.

As Buttkus stated, the corporation is currently implementing the projects on production transfer. Thus, this year the production of an innovative orphan drug for the treatment of patients with multiple myeloma has begun. Three more drugs will be localized soon, after which production will begin.

Takeda Pharmaceutical is a global biopharmaceutical company whose activities are focused on innovative scientific developments. Now the corporation has offices in 80 countries, where it employs more than 50 thousand people.

Made in Russia // Made in Russia

Author: Ksenia Gustova